ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm

NEW YORK, Sept. 15, 2020

Rosetta Stone Inc. (NYSE: RST) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Cambium Learning Group for $30 per share. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/rosetta-stone-inc-rst-stock-merger-cambium.

Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a consortium that includes members of Cellular Biomedicine management and several entities. Under the terms of the merger, Cellular Biomedicine stockholders (excluding certain parties) will receive $19.75 in cash for each outstanding share of common stock held immediately prior to the effective time of the merger. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/cellular-biomedicine-group-inc-cbmg-stock-merger

Immunomedics, Inc. (NASDAQ: IMMU) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Gilead Sciences, Inc. for $88.00 per share. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/immunomedics-merger-stock-gilead.

Proteostasis Therapeutics, Inc. (NASDAQ: PTI) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Yumanity Therapeutics. Under the terms of the merger agreement, Proteostasis will acquire all outstanding shares of Yumanity in exchange for newly-issued shares of Proteostasis common stock, with existing Proteostasis shareholders expected to own approximately 32.5% of the combined company. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/proteostasis-therapeutics-inc-pti-yumanity-stock-merger.

Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.